Skip to main content

Advertisement

Table 3 Favorable response (complete plus partial) by patient subgroup (N = 101)

From: Caspofungin Use in Daily Clinical Practice for Treatment of Invasive Aspergillosis: Results of a Prospective Observational Registry

Variable Favorable response
% (n/N) [95%CI]
Overall 56.4 (57/101) [46.7; 66.1]
Probable aspergillosis 56.3 (40/71) [44.0; 68.1]
Proven aspergillosis 56.7 (17/30) [37.4; 74.5]
Combination therapy 56.3 (9/16) [29.9; 80.2]
   First line 60.0 (3/5) [14.6; 94.7]
   Second Line 54.6 (6/11) [23.4; 83.3]
Monotherapy 56.5 (48/85) [45.3; 67.2]
   First line 60.0 (9/15) [32.3; 83.7]
   Second Line 55.7 (39/70) [43.3; 67.6]
First-line therapy 60.0 (12/20) [36.1; 80.9]
Salvage therapy 55.6 (45/81) [44.1; 66.6]
Culture examination performed 62.3 (38/61) [50.1; 74.5]
   Positive 55.6 (15/27) [36.9; 76.6]
   Negative 67.6 (23/34) [49.5; 82.6]
Neutropenic status at start of caspofungin therapy  
   ANC < 500 cells/μL 52.5 (31/59) [39.1; 65.7]
   ANC > = 500 cells/μL 61.9 (26/42) [45.6; 76.4]
Risk factors  
   Active malignancy 51.9 (41/79) [40.4; 63.3]
   AIDS/HIV infection 66.7 (2/3) [9.4; 99.2]
   Bone marrow/stem cell transplantation 53.6 (15/28) [33.9; 72.5]
• Autologous HSCT 40.0 (2/5) [5.3; 85.3]
• Allogeneic HSCT 56.5 (13/23) [34.5; 76.8]
   Diabetes mellitus 57.1 (8/14) [28.9; 82.3]
   Immunosuppressive medication 60.8 (45/74) [48.8; 72.0]
   Neutropenia at the time of hospitalization 53.0 (35/66) [40.3; 65.4]
   Prior fungal colonization 61.1 (11/18) [35.7; 82.7]
   Organ transplantation 75.0 (6/8) [34.9; 96.8]
  1. Response evaluated in N = 101 patients.